Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
Journal article published in 2017 by
C. Michael Gibson,
Gerald Chi 
,
Rim Halaby,
Serge Korjian,
Yazan Daaboul,
Purva Jain,
Douglas Arbetter,
Samuel Z. Goldhaber,
Russel Hull,
Adrian F. Hernandez
,
Rim Halaby,
Serge Korjian,
Yazan Daaboul,
Purva Jain,
Douglas Arbetter,
Samuel Z. Goldhaber,
Russel Hull,
Adrian F. Hernandez
